(Q36625236)

English

Inhibitors of signal transduction protein kinases as targets for cancer therapy

scientific article published on January 2006

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

1 reference

Europe PubMed Central

Inhibitors of signal transduction protein kinases as targets for cancer therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

3

object named as

Ugo Moens

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

author name string

Theresa Mikalsen

1

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Nancy Gerits

2

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

publication date

1 January 2006

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Biotechnology Annual Review

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

153-223

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

The origins of protein phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tyrosine kinases as targets for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The protein kinase complement of the human genome

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Signal transduction pathways in cancer development and as targets for cancer prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Issues and progress with protein kinase inhibitors for cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Tyrosine kinases as targets in cancer therapy - successes and failures

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel oncogenic protein kinase inhibitors for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Protein kinase inhibitors as a therapeutic modality

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cell biology. Lessons in rational drug design for protein kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Structural bioinformatics-based design of selective, irreversible kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Monoclonal antibodies as effective therapeutic agents for solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

RNA molecules as anti-cancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of glioma growth by tumor-specific activation of double-stranded RNA-dependent protein kinase PKR.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutic siRNAs

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Localized effects of cAMP mediated by distinct routes of protein kinase A.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulatory subunits of PKA and breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Minireview: PRKAR1A: normal and abnormal functions

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Structure, regulation and function of PKB/AKT--a major therapeutic target

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Structure and function of the epidermal growth factor (EGF/ErbB) family of receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapeutically targeted anticancer agents: inhibitors of receptor tyrosine kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Signaling through the epidermal growth factor receptor during the development of malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A small molecule-kinase interaction map for clinical kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical experience with CD64-directed immunotherapy. An overview

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Recent results and ongoing trials with panitumumab (ABX-EGF), a fully human anti-epidermal growth factor receptor antibody, in metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Structural basis for inhibition of the epidermal growth factor receptor by cetuximab

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Future directions in the use of antiangiogenic agents in patients with colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Overview of monoclonal antibodies in cancer therapy: present and promise

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical studies with non-iressa EGFR tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

VEGF-receptor signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Novel angiogenic signaling pathways and vascular targets

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The biology of vascular endothelial growth factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer. Encouraging results for second-generation antiangiogenesis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab in the treatment of breast cancer: rationale and current data

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

ZD6474--clinical experience to date

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of C

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of tyrosine kinase inhibitors in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Angiogenesis inhibitors under study for the treatment of lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer a

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Oncogenic derivatives of platelet-derived growth factor receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Kit as a human oncogenic tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of FLT3 in haematopoietic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

FLT-3: a new focus in the understanding of acute leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I trial of daily oral 4'- N -benzoyl-staurosporine in combination with protracted continuous infusion 5-fluorouracil in patients with advanced solid malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of PKC412 (N-benzoyl-staurosporine), a novel oral protein kinase C inhibitor, combined with gemcitabine and cisplatin in patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Expression of the ALK tyrosine kinase gene in neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The emerging normal and disease-related roles of anaplastic lymphoma kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Anaplastic lymphoma kinase proteins in growth control and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Abl: the prototype of oncogenic fusion proteins

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Gastrointestinal stromal tumors: biology and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

AMN107: tightening the grip of imatinib

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

BMS-354825: a novel drug with potential for the treatment of imatinib-resistant chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The interplay between Src and integrins in normal and tumor biology

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical trials of intracellular signal transductions inhibitors for breast cancer--a strategy to overcome endocrine resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

p53, mutations, and apoptosis in genistein-exposed human lymphoblastoid cells

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Infantile leukemia and soybeans--a hypothesis

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Activation of AKT kinases in cancer: implications for therapeutic targeting

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The activation of Akt/PKB signaling pathway and cell survival.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

An expanding role for mTOR in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

mTOR-targeted therapy of cancer with rapamycin derivatives

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The TOR pathway: a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Recent advances in stress signaling in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulation of tumor cell motility by ERK mitogen-activated protein kinases

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The RAF proteins take centre stage

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Second nature: biological functions of the Raf-1 "kinase"

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutational analysis of the ARAF gene in human cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Raf kinase inhibitors in oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116).

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Kinase inhibition with BAY 43-9006 in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Melanoma genetics and the development of rational therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mutation analysis of the coding sequences of MEK-1 and MEK-2 genes in human lung cancer cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The MAPK signalling pathways and colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK)

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeting the mitogen-activated protein kinase cascade to treat cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Protein kinase C isozymes as potential targets for anticancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Protein kinase C (PKC) family in cancer progression

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Bryostatin-1: a novel PKC inhibitor in clinical development

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A multicentre phase II trial of bryostatin-1 in patients with advanced renal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I/II study of LY900003, an antisense inhibitor of protein kinase C-alpha, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and toxicity of the antisense oligonucleotide aprinocarsen directed against protein kinase C-alpha delivered as a 21-day continuous intravenous infusion in patients with recurrent high-grade astrocytomas

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The broad-range cyclin-dependent kinase inhibitor UCN-01 induces apoptosis in colon carcinoma cells through transcriptional suppression of the Bcl-x(L) protein.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The cyclin-dependent kinase inhibitor UCN-01 plus cisplatin in advanced solid tumors: a California cancer consortium phase I pharmacokinetic and molecular correlative trial

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of ILK in PTEN-mutant human glioblastomas inhibits PKB/Akt activation, induces apoptosis, and delays tumor growth.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrin-linked kinase, a promising cancer therapeutic target: biochemical and biological properties

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrin-linked kinase: a cancer therapeutic target unique among its ILK.

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of integrin-linked kinase by a selective small molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xe

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Regulation of tumor angiogenesis by integrin-linked kinase (ILK).

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Nanobodies as novel agents for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficient cancer therapy with a nanobody-based conjugate

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Colorectal cancer: mutations in a signalling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FS1387-2656%2806%2912006-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1387-2656(06)12006-2

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36625236&oldid=1774161788"